. 2015 Aug 12;61(12):1850–1861. doi: 10.1093/cid/civ687

Table 3.

Conditions With Significant Differences in Incidence Rates Between P1074 Participants in 2008–2014 and P219C Participants in 2004–2007^a

Category^a	P219C (2004–2007)				P1074 (2008–2014)				P1074 vs P219C
Category^a	Participants at Risk, No.	Events, No.	Total Person-Years	Rate/100 Person-Years	Participants at Risk, No.	Events, No.	Total Person-Years	Rate/100 Person-Years	IRR (95% CI)	IRR, Age-Adjusted^b (95% CI)
Significant Increases in IRs
Infectious conditions
Latent tuberculosis	2350	2	6443	0.031	1196	21	5345	0.393	12.66 (2.97–53.98)	12.62 (2.80–56.93)
Atypical mycobacterial infection	2325	1	6375	0.016	1183	8	5326	0.150	9.58 (1.20–76.56)	5.19 (.60–44.91)
Esophageal or pulmonary candidiasis	2279	7	6252	0.112	1160	23	5185	0.444	3.96 (1.70–9.23)	1.97 (.79–4.90)
Genital tract infections
Anogenital herpes	1607	6	3597	0.167	1069	24	4502	0.533	3.20 (1.31–7.82)	1.54 (.62–3.87)
HPV infection or disease	1563	38	3463	1.097	1024	79	4155	1.901	1.73 (1.18–2.55)	0.94 (.62–1.41)
Pregnancy	792	48	1771	2.710	512	97	1896	5.117	1.89 (1.34–2.67)	1.31 (.91–1.88)
Psychiatric and neurodevelopmental conditions
Substance abuse or alcohol abuse	2346	1	6441	0.016	1186	24	5290	0.454	29.22 (3.95–216.00)	10.72 (1.40–81.89)
Anxiety disorders	2347	7	6435	0.109	1172	38	5195	0.731	6.72 (3.00–15.06)	4.36 (1.83–10.42)
Trauma/stress-related disorders	2351	4	6445	0.062	1189	16	5318	0.301	4.85 (1.62–14.50)	4.27 (1.31–13.96)
Psychiatric disorders (any)	2260	58	6133	0.946	1061	124	4492	2.760	2.92 (2.14–3.99)	1.95 (1.39–2.74)
Disruptive/impulse control disorders	2343	5	6422	0.078	1188	12	5318	0.226	2.90 (1.02–8.23)	4.63 (1.59–13.48)
Mood disorders	2280	47	6196	0.759	1092	102	4696	2.172	2.86 (2.03–4.05)	1.74 (1.20–2.53)
Learning and communication disorders	2046	26	5547	0.469	962	44	4170	1.055	2.25 (1.39–3.66)	4.66 (2.83–7.66)
Other conditions
Diabetes mellitus	2353	1	6454	0.015	1198	9	5381	0.167	10.79 (1.37–85.21)	4.94 (.57–42.70)
Vitamin D deficiency/metabolic bone disorders	2352	4	6444	0.062	1179	25	5281	0.473	7.63 (2.65–21.91)	6.56 (2.16–19.97)
Fractures	2343	4	6422	0.062	1183	17	5311	0.320	5.14 (1.73–15.27)	6.43 (2.06–20.11)
Appendicitis	2338	3	6407	0.047	1192	12	5349	0.224	4.79 (1.35–16.98)	4.55 (1.20–17.19)
Iron deficiency anemia	2305	14	6293	0.222	1145	39	5076	0.768	3.45 (1.88–6.36)	3.11 (1.60–6.04)
Gastroesophageal reflux disease	2313	7	6329	0.111	1161	19	5195	0.366	3.31 (1.39–7.87)	2.62 (1.00–6.84)
Hepatitis, nonspecific	2298	6	6308	0.095	1153	16	5151	0.311	3.27 (1.28–8.35)	2.54 (.96–6.77)
Eczema	2127	11	5811	0.189	1019	25	4501	0.555	2.93 (1.44–5.96)	4.22 (1.95–9.12)
Dyslipidemia	2349	8	6429	0.124	1174	18	5242	0.343	2.76 (1.20–6.35)	3.40 (1.37–8.42)
Hypertension	2328	16	6372	0.251	1156	34	5147	0.661	2.63 (1.45–4.77)	1.38 (.73–2.62)
Asthma	1935	27	5250	0.514	884	47	3844	1.223	2.38 (1.48–3.82)	3.07 (1.84–5.13)
Hypothyroidism	2356	0	6461	0.000	1191	8	5352	0.149	NC^c	NC^c
Hyperthyroidism	2358	0	6467	0.000	1200	5	5404	0.093	NC^c	NC^c
Significant decreases in IRs
Pneumonia	1571	73	4201	1.738	811	41	3508	1.169	0.67 (.46–.99)	0.62 (.41–.95)

Abbreviations: CI, confidence interval; HPV, human papillomavirus; IRs, incidence rates; IRRs, IR ratios; NC, not calculated.

^a Conditions are defined in greater detail in Supplementary Text 1.

^b Age-adjusted models fit using Poisson regression models with effects for study and age group (<10, 10–14, 14–18, or ≥18 years).

^c Not calculated because there were no events in the P219C study.